Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

Mark J Sculpher, Greta Lozano-Ortega, Jennifer Sambrook, Stephen Palmer, Orges Ormanidhi, Ameet Bakhai, Marcus Flather, P Gabriel Steg, Shamir R Mehta, William Weintraub

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)


The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.
Original languageEnglish
Pages (from-to)845-852
Number of pages8
JournalAmerican Heart Journal
Issue number5
Publication statusPublished - May 2009


  • Acute Coronary Syndrome
  • Anticoagulants
  • Cost-Benefit Analysis
  • Electrocardiography
  • Enoxaparin
  • Factor X
  • Follow-Up Studies
  • Guideline Adherence
  • Health Care Costs
  • Humans
  • Polysaccharides
  • Practice Guidelines as Topic
  • Time Factors
  • United States

Cite this